Bladder Cancer

Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.

Data from the phase 3 EV-302 trial support enfortumab vedotin plus pembrolizumab as a potential standard of care in locally advanced or metastatic urothelial carcinoma.

Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.

A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.

Investigators will continue to assess overall survival in patients treated with pembrolizumab for localized muscle-invasive urothelial carcinoma as part of the phase 3 AMBASSADOR trial.

Combining pembrolizumab with enfortumab vedotin-ejfv significantly improves responses vs chemotherapy among patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.

Real-world data suggest that the presence of pelvic lymphadenopathy should not be viewed as a contraindication to trimodality therapy in nonmetastatic clinically node-positive bladder cancer.

Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.

Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.

During Morning Rounds, Petros Grivas, MD, and his treating team debate the diagnosis of a patient with urothelial carcinoma as it has an unusual presentation.

Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.

In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.

Shared patient perspectives and conversation centered around collaboration in clinical care for metastatic bladder cancer, including the oncology pharmacists’ role in treatment decisions.

Rohit Jain, MD, MPH provides an overview of metastatic bladder cancer, discussing differences in urothelial carcinoma based on location, patient presentations, diagnosis, and staging.

Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.

A brief discussion on optimal follow-up practices with patients on therapy for advanced bladder cancer.

Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses what strategies are being used to treat patients with bladder cancer during the chemotherapy shortage.

Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

Investigators of a meta-analysis report no significant difference in outcomes when comparing trimodality therapy and radical cystectomy for the treatment of muscle-invasive bladder cancer.

Genitourinary cancer experts share insight on best practices in educating patients on treatment schedules and adverse events when receiving therapy for advanced bladder cancer.

Focused discussion on the optimal use of radiation therapy strategies, alone or in combination with systemic therapy, for patients with advanced bladder cancer.

Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.

Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

The combination also demonstrates no new safety signals in patients with uresectable or metastatic disease and meets the phase 3 CheckMate-901 study’s primary survival end points.

Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.

Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.